Cadila's Dabhasa facility receives Establishment Inspection Report
Cadila Healthcare announced that the company's API manufacturing facility located at Dabhasa, Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 7 to 11 October 2019. The EIR report stated that the
classification of the facility is 'No Action Indicated (NAI)'.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Dec 06 2019 | 3:28 PM IST